Docoh
Loading...

CALA Calithera Biosciences

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Friday
14 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Friday's session, 445 companies made new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
12 Health Care Stocks Moving In Friday's Intraday Session
31 Dec 21
Intraday Update, Markets, Movers
Calithera Bioscience Granted European Patent Titled 'ARGINASE INHIBITOR COMBINATION THERAPIES'
17 Dec 21
News, Legal
https://register.epo.org/application?number=EP17801266
12 Health Care Stocks Moving In Wednesday's After-Market Session
1 Dec 21
Movers
Gainers Hoth Therapeutics (NASDAQ:HOTH) shares moved upwards by 6.08% to $0.86 during Wednesday's after-market session. The company's market cap stands at $20.6 million.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Nov 21
Pre-Market Outlook, Markets, Movers
4 Penny Stocks Insiders Are Buying
11 Nov 21
News, Penny Stocks, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Calithera Biosciences Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M
9 Nov 21
Earnings, News
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 53.13 percent increase over losses of $(0.32) per share
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
9 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
9 Nov 21
Earnings, M&A, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
8 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
HC Wainwright & Co. Downgrades Calithera Biosciences to Neutral
8 Nov 21
News, Downgrades, Analyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Calithera Biosciences (NASDAQ:CALA) from Buy to Neutral.
12 Health Care Stocks Moving In Friday's Intraday Session
5 Nov 21
Intraday Update, Markets, Movers
William Blair Downgrades Calithera Biosciences to Market Perform
5 Nov 21
News, Downgrades, Analyst Ratings
William Blair analyst Matt Phipps downgrades Calithera Biosciences (NASDAQ:CALA) from Outperform to Market Perform.
Why Did Calithera Shares Dropped To 52-Week Low In Premarket Friday?
5 Nov 21
Biotech, News, Penny Stocks, Short Ideas, Health Care, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 Nov 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
5 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Calithera Posts Early-Data For Arginase Inhibitor In Cystic Fibrosis Trial
1 Nov 21
Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

Press releases

From Benzinga Pro
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
7 Jan 22
Press Releases
MENLO PARK, Calif., Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet
Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference
5 Jan 22
News, Press Releases
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the
Thinking about buying stock in Dicerna Pharmaceuticals, Cloopen Group, Calithera Biosciences, ZTO Express, or Macy's?
18 Nov 21
Opinion, Press Releases
NEW YORK, Nov. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRNA, RAAS, CALA, ZTO, and M.
Calithera to Present at the 2021 Jefferies London Healthcare Conference
12 Nov 21
News, Press Releases
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
5 Nov 21
News, Management, Press Releases
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the promotion of current vice
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
5 Nov 21
Health Care, Press Releases
--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired targeted oncology compounds sapanisertib and mivavotinib, as
Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021
1 Nov 21
Health Care, Analyst Ratings, Press Releases
-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects-- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride-- Early positive trend
Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021
21 Oct 21
News, Health Care, Press Releases
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the